Yahoo Web Search

Search results

1. • For some endometriosis-related ovarian cancers, timing is everything

     Medical Xpress· 1 day ago

     Clear cell ovarian carcinoma comprises 5%–12% of ovarian cancer cases and is resistant to chemotherapy. Endometrioid ...

2. • Juncell Therapeutics Announces Clinical Data of GC203 TIL therapy in Ovarian Cancer at ASCO 2024

     KTLA-TV Los Angeles· 5 days ago

     (Juncell Therapeutics), a clinical-stage biotech developing innovative Tumor-Infiltrating Lymphocyte (TIL) therapies for cancers, announced latest clinical research results ...

3. • 

     Docs support drug regulator’s move to withdraw Olaparib for some cancer patients

     Investing.com· 7 days ago

     Olaparib is a chemotherapy drug and is used to treat certain kinds of cancers of the ovaries,...

4. • Penn Medicine at the 2024 ASCO Annual Meeting | Newswise

     Newswise· 7 days ago

     Researchers from Penn Medicine’s Abramson Cancer Center (ACC) and the Perelman School of Medicine at the University of Pennsylvania will present data on the latest advances ...

5. • 

     ASCO 2024: Verastem’s combo therapy for pancreatic cancer hits early trial success

     Clinical Trials Arena via Yahoo Finance· 5 days ago

     Avutometinib won orphan drug designation from the US Food and Drug Administration (FDA) in March...

6. • Theratechnologies’ Sudocetaxel Zendusortide ASCO 2024 Presentation Demonstrates Signs of Long-Term...

     Digital Journal· 6 days ago

     Poster highlights durable disease stabilization lasting beyond treatment completionResults suggest a unique, multimodal mechanism of action that differs from other cancer ...

7. • Targeting 'monster cancer cells' could reduce recurrence rates after cancer therapy

     Medical Xpress· 1 day ago

     Both types of therapy put cancer cells under stress, with the goal of causing them to self-destruct. Recently, scientists have begun to look at the role of polyploid giant ...

8. • 

     Rutgers Cancer Institute and RWJBarnabas Health Se | Newswise

     Newswise· 7 days ago

     Clinicians and scientists from Rutgers Cancer Institute and RWJBarnabas Health will lead sessions...

9. • AbbVie Showcases Robust Solid Tumor Pipeline at ASCO 2024 with New Data from Its Innovative...

     WROC Rochester· 1 day ago

     New safety and efficacy data in heavily pre-treated patients with metastatic colorectal cancer (CRC), from a Phase 1 study of ABBV-400, a next-generation, potential best-in-class ...

10. • 

      What's Going On With Mid-Cap Cancer-Focused Verastem Oncology Stock On Friday?

      Benzinga via AOL· 5 days ago

      :VSTM) announced the initial interim safety and efficacy results from the ongoing RAMP 205 Phase 1/2...